Emris Pharma, a recent spin-off of Hadasit Medical Research Services and Development Ltd. and Yissum Research Development Co., has started development of a new topical drug to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors used to treat cancer.